Rift Biotherapeutics

SalvaRx led a Series A investment into Rift Biotherapeutics("Rift") in March 2017.  Rift, an early stage research and development company, was founded in 2015 in order to discover and develop first-in-class antibodies to targets implicated in the inflammed state of the tumour microenvironment.  Rift has a small lab space in San Diego, California and has recently won the Boehringer Ingelheim Innovation prize, entitling it to additional lab space at BioLabs San Diego, a Southern California based incubator for biotech start-ups.


The most recent information about Rift Biotherapeutics can be found on its website, riftbio.com